Glucocorticoid treatment in community-acquired pneumonia

The Lancet

Volumn 377, Issue 9782, 2011, Pages 1982-1984

  Confalonieri, Marco ^a   Meduri, G Umberto ^b  

^a UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DEXAMETHASONE; GLUCOCORTICOID; METHYLPREDNISOLONE;

COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; HUMAN; INFLAMMATION; LOW DRUG DOSE; MORTALITY; NOTE; PRIORITY JOURNAL; SEPSIS;

EID: 79958772491     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60777-0     Document Type: Note

References (12)

1. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281: 61-66. (Pubitemid 29025101)
2. Kaplan V, Clermont G, Griffin MF, et al. Pneumonia: still the old man's friend? Arch Intern Med 2003; 163: 317-23. (Pubitemid 36183860)
3. Meijvis SCA, Hardeman H, Remmelts HHF, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; published online June 1. DOI:10.1016/S0140-6736(11)60607-7.
4. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37. (Pubitemid 28421502)
5. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301: 2362-75.
6. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171: 242-48.
7. Meduri GU. An historical review of glucocorticoid treatment in sepsis. Disease pathophysiology and the design of treatment investigation. Sepsis 1999; 3: 21-38. (Pubitemid 29441352)
8. Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest 2009; 136: 1631-43.
9. Kellum JA, Kong L, Fink MP, et al, for the GenIMS Investigators. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167: 1655-63. (Pubitemid 47280347)
10. Yende S, D'Angelo G, Kellum JA, et al, for the GenIMS Investigators. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177: 1242-47. (Pubitemid 351860933)
11. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-22. (Pubitemid 37413536)
12. Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011; published online April 21. DOI:10.1097/CCM.0b013e31821b8290.